The effect of plasminogen activator inhibitor-1 -675 4G/5G polymorphism on PAI-1 gene expression and adipocyte differentiation

Clinical and Applied Thrombosis/Hemostasis

Volumn 14, Issue 4, 2008, Pages 438-446

  Ozel Demiralp, Duygu ^a   Aktas, Huseyin ^b   Akar, Nejat ^a  

^a ANKARA UNIVERSITY   (Turkey)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Ciglitazone; Human umbilical cord vein endothelial cells; Plasminogen activator 1; Troglitazone

Indexed keywords

CIGLITAZONE; GLUCOSE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; TROGLITAZONE;

ADIPOCYTE; ADIPOGENESIS; ANIMAL CELL; ARTICLE; BIOASSAY; CELL DIFFERENTIATION; CELL PROTECTION; CONTROLLED STUDY; GENE EXPRESSION; GENE EXPRESSION REGULATION; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; GENETIC PREDISPOSITION; GENOTYPE; GLUCOSE TRANSPORT; HUMAN; HUMAN CELL; INSULIN RESISTANCE; MOUSE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROMOTER REGION; PROTEIN EXPRESSION;

3T3-L1 CELLS; ADIPOCYTES; ANIMALS; CELL DIFFERENTIATION; CELLS, CULTURED; CHROMANS; HUMANS; INSULIN RESISTANCE; MICE; PLASMINOGEN ACTIVATOR INHIBITOR 1; POLYMORPHISM, GENETIC; PPAR GAMMA; PROMOTER REGIONS (GENETICS); THIAZOLIDINEDIONES;

EID: 51849162523     PISSN: 10760296     EISSN: None     Source Type: Journal    
DOI: 10.1177/1076029607305081     Document Type: Article

References (31)

1. Alessi MC, Peiretti F., Morange P., Henry M., Nalbone G., Juhan-Vague I. Production of plasminogen activator inhibitor 1 by human adipose tissue: possible link between visceral fat accumulation and vascular disease. Diabetes. 1997 ; 46: 860-867.
2. Asplund-Carlson A., Hamsten A., Wiman B., Carlson LA Relationship between plasma plasminogen activator inhibitor-1 activity and VLDL triglyceride concentration, insulin levels and insulin sensitivity: studies in randomly selected normal and hypertriglyceridaemic men. Diabetologia. 1993 ; 36: 817-825.
3. Combs TP, Pajvani UB, Berg AH, et al. A transgenic mouse with a deletion in the collagenous domain of adiponectin displays elevated circulating adiponectin and improved insulin sensitivity. Endocrinology. 2004 ; 145: 367-383.
4. Estelles A., Dalmau J., Falco C., et al. Plasma PAI-1 levels in obese children-effect of weight loss and influence of PAI-1 promoter 4G/5G genotype. Thromb Haemost. 2001 ; 86: 647-652.
5. Doggen CJM, Bertina RM, Cats VM, Reitsma PH, Rosendaal FR The 4G/5G polymorphism in the plasminogen activator inhibitor-1 gene is strongly associated with obesity. Diabetologia. 2002 ; 45: 584-587.
6. Lehmann JM, Moore LB, Smitholiver TA, Wilkison WO, Willson TM, Kliewer SA An antidiabetic thiazolidinedione is a high-affinity ligand for peroxisome-proliferator activated receptor gamma (PPAR-gamma). J Biol Chem. 1995 ; 270: 12953-12956.
7. Issemann I., Green S. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators. Nature (Lond). 1990 ; 347: 645-650.
8. Akar N., Akar E., Yilmaz E., Deda G. Plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish children with cerebral infarct and effect on factor V 1691 A mutation. J Child Neurol. 2001 ; 16: 294-295.
9. Berberoǧlu M., Evliyaoǧlu O., Adiyaman P., et al. Plasminogen activator inhibitor-1 (PAI-1) gene polymorphism (-675 4G/5G) associated with obesity and vascular risk in children. J Pediatr Endocrinol Metab. 2006 ; 19: 741-748.
10. Liang X., Kanjanabuch T., Mao S-L., et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab. 2005 ; 10: 1152-1153.
11. Lambert V., Munaut C., Noel A., et al. Influence of plasminogen activator inhibitor type 1 on choroidal neovascularization. FASEB J. 2001 ; 15: 1021-1027.
12. Deng X., Li H., Tang YW Cytokine expression in respiratory syncytial virus-infected mice as measured by quantitative reverse-transcriptase PCR. J Virol Methods. 2003 ; 107: 141-146.
13. Dong J., Fujii S., Li H., et al. Interleukin-6 and mevastatin regulate plasminogen activator inhibitor-1 through CCAAT/enhancer-binding protein-δ. Arterioscler Thromb Vasc Biol. 2005 ; 25: 1078-1084.
14. Debrock S., Declerck PJ Neutralization of plasminogen activator inhibitor-1 inhibitory properties: identification of two different mechanisms. Biochim Biophys Acta. 1997 ; 1337: 257-266.
15. Akar N., Yilmaz E., Akar E., Avcu F., Yalcin A., Cin S. Effect of plasminogen activator inhibitor-1 4G/5G polymorphism in Turkish deep vein thrombotic patients with and without FV1691G-A. Thromb Res. 2000 ; 97: 227-230.
16. Haffner SM, D'Agostino R. Jr, Mykkanen L., et al. Insulin sensitivity in subjects with type 2 diabetes relationship to cardiovascular risk factors: the insulin resistance atherosclerosis study. Diabetes Care. 1999 ; 22: 562-568.
17. Cigolini M., Targher G., Seidell JC, et al. Relationships of plasminogen activator inhibitor-1 to anthropometry, serum insulin, triglycerides and adipose tissue fatty acids in healthy men. Atherosclerosis. 1994 ; 106: 139-147.
18. Landin K., Stigendahl L., Eriksson E., et al. Abdominal obesity is associated with an impaired fibrinolytic activity and elevated plasminogen activator inhibitor-1. Metabolism. 1990 ; 39: 1044-1048.
19. Sawdey MS, Loskutoff DJ Regulation of murine type 1 plasminogen activator inhibitor gene expression in vivo. Tissue specificity and induction by lipopolysaccharide, tumor necrosis factor-alpha, and transforming growth factor-beta. J Clin Invest. 1991 ; 88: 1346-1353.
20. Lin FT, Lane MD CCAAT/enhancer binding protein alpha is sufficient to initiate the 3T3-L1 adipocyte differentiation program. Proc Natl Acad Sci U S A. 1994 ; 91: 8757-8761.
21. Liang X., Kanjanabuch T., Mao S., et al. Plasminogen activator inhibitor-1 modulates adipocyte differentiation. Am J Physiol Endocrinol Metab. 2005 ; 290: E103 - E113.
22. Rosen ED, Hsu CH, Wang X., et al. C/EBPα induces adipogenesis through PPARγ: a unified pathway. Genes Dev. 2002 ; 16: 22-26.
23. Rosen ED, Walkey CJ, Puigserver P., Spiegelman BM Transcriptional regulation of adipogenesis. Genes Dev. 2000 ; 14: 1293-1307.
24. Wu Z., Rosen ED, Brun R., et al. Cross-regulation of C/EBP alpha and PPAR gamma controls the transcriptional pathway of adipogenesis and insulin sensitivity. Mol Cell. 1999 ; 3: 151-158.
25. Evans RM, Barish GD, Wang YX PPARs and the complex journey to obesity. Nat Med. 2004 ; 10: 355-361.
26. Aktas H., Cai H., Cooper GM Ras links growth factor signaling to the cell cycle machinery via regulation of cyclin D1 and the Cdk inhibitor p27KIP1. Mol Cell Biol. 1997 ; 17: 3850-3857.
27. Kudo M., Sugawara A., Uruno A., Takeuchi K., Ito S. Transcription suppression of peroxisome proliferator-activated receptor γ2 gene expression by tumor necrosis factor α via an inhibition of CCAAT/enhancer-binding protein δ during the early stage of adipocyte differentiation. Endocrinology. 2004 ; 145: 4948-4956.
28. Picard F., Auwerx J. PPAR (gamma) and glucose homeostasis. Annu Rev Nutr. 2002 ; 22: 167-197.
29. Barroso I., Gurnell M., Crowley VE, et al. Dominant negative mutations in human PPARγ associated with severe insulin resistance, diabetes mellitus and hypertension. Nature. 1999 ; 402: 880-883.
30. He W., Barak Y., Hevener A., et al. Adipose-specific peroxisome proliferator-activated receptor gamma knockout causes insulin resistance in fat and liver but not in muscle. Proc Natl Acad Sci USA. 2003 ; 100: 15712-15717.
31. Oishi K., Ohkura N., Amagai N., Ishida N. Involvement of circadian clock gene Clock in diabetes-induced circadian augmentation of plasminogen activator inhibitor-1 (PAI-1) expression in the mouse heart. FEBS Lett. 2005 ; 579: 3555-3559.